International Association of Scientists
www.iasnetedu.com

**Available online at www.jobiost.com**
**IJBLS 2023; 2(2):274-280**

International Journal of BioLife Sciences

Original paper

# Precision Medicine: Pioneering Advances in Molecular Oncology and Therapy in Colorectal Cancer

Marjan Salehi*

MSc of Microbiology, Department of Microbiology, Islamic Azad University, Qom branch, Qom, Iran

***Received**: 9 October 2023* ***Revised**: 13 October 2023* ***Accepted**: 17 October 2023*

**Abstract**

**Background and aim:** Pioneering advances in molecular oncology and therapy have played a pivotal role in advancing our understanding and treatment of colorectal cancer. This paper provides an overview of the significant advancements in molecular oncology and therapy specifically tailored for colorectal cancer.

**Materials and methods:** A literature review was conducted to gather insights into genomic profiling, targeted therapies, immunotherapy, and liquid biopsies, focusing on personalized treatment approaches. The review emphasizes recent pioneering advances, their impact on patient outcomes, and the evolving landscape of precision medicine in colorectal cancer.

**Results:** Targeted therapies, particularly anti-EGFR agents, and immune checkpoint inhibitors like PD-1 and CTLA-4 inhibitors, show promise in treating colorectal cancer, especially in patients with specific genetic mutations, microsatellite instability (MSI), or high tumor mutational burden (TMB). Immunotherapeutic approaches, such as cancer vaccines and CAR-T cell therapy, hold potential for enhancing immune responses against colorectal cancer cells. Additionally, analyzing circulating tumor DNA and biomarkers in blood samples provides real-time information on tumor dynamics, aiding treatment decisions and detecting minimal residual disease. These advancements offer hope for improved outcomes in colorectal cancer patients.

**Conclusion:** In conclusion, molecular oncology and therapy have advanced significantly, enhancing our understanding and management of colorectal cancer. Genomic profiling, targeted therapies, immunotherapy, and liquid biopsies have enabled personalized treatment approaches, improving outcomes and quality of life for patients. Ongoing research and collaboration are crucial for further progress and the development of more effective interventions for this prevalent malignancy.

**Keywords:** *Precision medicine, Oncology, Colon cancer*

***Corresponding author:** Marjan Salehi, MSc of Microbiology, Department of microbiology, Islamic Azad University, Qom branch, Qom, Iran.
**E-mail address**: marjaanii1393@gmail.com

## Introduction

Precision medicine has emerged as a transformative approach in the field of oncology, revolutionizing the diagnosis, treatment, and management of cancer. With its foundation rooted in molecular oncology, precision medicine aims to tailor therapeutic strategies to the unique genetic makeup and molecular characteristics of individual patients and their tumors [1]. This paradigm shift has paved the way for unprecedented breakthroughs in cancer research and therapy, offering new avenues for improved patient outcomes and personalized care [2].

In this review article, we delve into the pioneering advances in molecular oncology and therapy that have propelled precision medicine to the forefront of cancer management. We explore the remarkable progress made in understanding the intricate molecular mechanisms driving tumorigenesis, the identification of predictive biomarkers, and the development of targeted therapies that specifically address the underlying molecular alterations driving cancer progression [3].

One of the key pillars of precision medicine is the comprehensive analysis of genomic alterations in tumors. The advent of next-generation sequencing technologies has enabled researchers to unravel the complex genomic landscapes of various cancer types, uncovering previously unknown driver mutations and mutational signatures [4]. These insights have led to the identification of numerous actionable molecular targets that can be exploited for therapeutic intervention [5].

Furthermore, the integration of high-throughput technologies, such as transcriptomics, proteomics, and metabolomics, has expanded our understanding of the functional consequences of genetic alterations and their impact on signaling pathways and cellular processes. This multi-omics approach has provided a more comprehensive view of the molecular intricacies underlying cancer development and has facilitated the discovery of novel therapeutic targets [6].

In parallel, the development of targeted therapies has witnessed remarkable progress. Small molecule inhibitors and monoclonal antibodies have been designed to selectively target specific molecular aberrations, disrupting the signaling cascades that promote tumor growth and survival [7]. These precision therapies have showcased remarkable success in several cancer types, improving response rates, prolonging survival, and minimizing adverse effects compared to conventional chemotherapy [8].

Moreover, the advent of immunotherapy, specifically immune checkpoint inhibitors, has redefined cancer treatment approaches. By unleashing the power of the immune system to recognize and eliminate cancer cells, immunotherapies have demonstrated unprecedented clinical responses in various malignancies [9]. Precision medicine plays a pivotal role in identifying patients who are most likely to benefit from immune checkpoint blockade through the assessment of specific molecular markers, such as tumor mutational burden and PD-L1 expression [10].

Despite these remarkable advancements, challenges and limitations persist in the field of precision medicine. Resistance mechanisms, tumor heterogeneity, and the complexity of molecular networks present ongoing hurdles that require further investigation and innovative approaches. Additionally, the integration of precision medicine into routine clinical practice poses logistical and ethical considerations, necessitating collaborative efforts between researchers, clinicians, and regulatory bodies [11].

Precision medicine has ushered in a new era of molecular oncology and therapy, transforming the landscape of cancer treatment. This review article aims to provide a comprehensive overview of the pioneering advances in the field, highlighting the remarkable progress made in understanding the molecular underpinnings of cancer and the development of targeted therapies. By harnessing the power of precision medicine, we strive to optimize cancer care, enhance patient outcomes, and

ultimately pave the way for a future where personalized and effective treatments are the norm in oncology [12].

- *Introduction to Precision Medicine in Oncology*

Precision medicine has revolutionized the field of oncology by tailoring treatment strategies to individual patients based on their unique genetic and molecular characteristics. This approach seeks to maximize treatment efficacy while minimizing adverse effects. The foundation of precision medicine lies in molecular oncology, which involves unraveling the complex molecular mechanisms driving cancer development and progression [13].

- *Genomic Analysis and Molecular Profiling*

One of the key components of precision medicine is the comprehensive analysis of genomic alterations in tumors. Next-generation sequencing technologies have played a pivotal role in identifying driver mutations and mutational signatures across various cancer types. This genomic profiling has led to the discovery of actionable molecular targets and the development of targeted therapies [14].

- *Multi-Omics Approaches in Precision Medicine*

In addition to genomic analysis, the integration of other high-throughput technologies, such as transcriptomics, proteomics, and metabolomics, has provided a more comprehensive understanding of the functional consequences of genetic alterations. Multi-omics approaches have elucidated the intricate molecular networks and signaling pathways involved in cancer development. This knowledge has facilitated the identification of novel therapeutic targets and potential biomarkers for patient stratification [15].

- *Targeted Therapies in Precision Oncology*

Targeted therapies have emerged as a cornerstone of precision medicine. These therapies are designed to specifically inhibit or modulate molecular targets that drive tumor growth and survival. Small molecule inhibitors and monoclonal antibodies have been developed to selectively target aberrant signaling pathways and oncogenic drivers. Examples include tyrosine kinase inhibitors, immune checkpoint inhibitors, and hormone receptor antagonists. Targeted therapies have demonstrated remarkable success in certain cancer types, improving patient outcomes and quality of life [3].

- *Immunotherapy and Precision Medicine*

Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment by harnessing the power of the immune system to recognize and eliminate cancer cells. Precision medicine plays a crucial role in identifying patients who are most likely to benefit from immunotherapy based on specific molecular markers, such as tumor mutational burden and PD-L1 expression. Biomarker-driven immunotherapy has shown significant clinical responses, particularly in melanoma, lung cancer, and bladder cancer [4].

- *Challenges and Future Directions*

While precision medicine has made substantial strides in cancer management, several challenges remain. Resistance mechanisms, tumor heterogeneity, and the complexity of molecular networks pose ongoing hurdles in achieving long-term treatment success. Additionally, the integration of precision medicine into routine clinical practice requires addressing logistical and ethical considerations. Collaborative efforts among researchers, clinicians, and regulatory bodies are essential to overcome these challenges and ensure the widespread implementation of precision medicine [16].

- *Precision Medicine, in the Treatment of Colon Cancer, is Utilized as Follows:*

Accurate Diagnosis: By employing genomic-based technologies and biomarker tests, precise

identification of specific genetic compositions present in colon cancer becomes possible. These tests can indicate positive alterations in genes such as KRAS, NRAS, and BRAF, which play a significant role in tumor development and treatment response [17].

Targeted Therapy: The precise understanding of molecular compositions in colon cancer enables the development of targeted therapies. For instance, anti-EGFR antibodies like cetuximab and panitumumab have shown considerable improvement in patients with wild-type KRAS and NRAS genes. These targeted therapies, by inhibiting the EGFR signaling pathway, yield better outcomes in selected patients [18].

Immune Checkpoint Inhibitors and Protein Mismatch: Patients with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) in colon cancer respond well to immune checkpoint inhibitors such as pembrolizumab and nivolumab. These drugs, by blocking proteins like PD-1 or PD-L1, enhance the body's immune response and enable better recognition and attack of cancer cells by immune cells [19].

Mechanisms of Resistance and Combination Therapy: Although targeted therapies and immunotherapies have shown significant benefits, resistance mechanisms can limit their long-term effectiveness. The goal of precision medicine is to identify secondary genetic changes and develop combination therapies. For example, the combination of BRAF inhibitors (in precision medicine for colon cancer treatment) is based on an approach that considers the unique genetic and molecular characteristics of individual patients and their tumors. The approach of precision medicine holds great promise in improving patient outcomes and optimizing treatment efficacy [20].

## Material and Methods

For the accurate diagnosis of genetic compositions in colon cancer, several tests are used to provide information about mutations and genetic alterations in cancer cells.

Below are some common tests used for the precise diagnosis of genetic compositions in colon cancer:

- *DNA Sequencing Tests:*

These tests utilize DNA sequencing technology to examine the exact sequence of nucleotides in tissue or blood samples. They can identify mutations and genetic alterations in genes associated with colon cancer, such as KRAS, NRAS, and BRAF genes [21].

- *PCR Tests:*

PCR (Polymerase Chain Reaction) tests are used to amplify specific copies of DNA in colon cancer samples. These tests can detect specific mutations in target genes.

- *FISH Tests:*

FISH (Fluorescence in Situ Hybridization) tests use hybridization technology to identify specific regions of DNA in cancer cells. These tests can be helpful in detecting structural changes in genes related to colon cancer [22].

- *NGS Tests:*

NGS (Next-Generation Sequencing) tests utilize DNA sequencing technology to analyze further details of the genome of cancer cells. These tests can detect mutations, structural changes, and other genetic compositions in cancer cells [23].

These tests, along with other molecular tests, can assist physicians and healthcare professionals in identifying specific genetic compositions present in colon cancer and determining personalized treatment plans. However, for a more accurate and comprehensive diagnosis, further discussion with a healthcare professional regarding the specific tests and their interpretation is recommended.

## Discussion

In one study in 2022 Fortunato Ciardiello and his colleagues worked on oncology treatment and revealed as a result that, the next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine- based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC Nguyen H [24].

The other study by Nguyen H. Tran has reported that KRAS mutations at exon 2 predict resistance to EGFR targeted therapies. More recently the data have expanded to include KRAS mutations at exons 3 and 4 and NRAS mutations at exons 2, 3 and 4 as well as other biomarkers including BRAF and PIK3CA, leading to the evolution of the treatment of mCRC to a more precision-based approach. As our understanding of relevant biomarkers increases, and data from both molecular profiling and treatment response become more readily available, treatment options will become more precise and their outcomes more effective [19].

Julian E. Riedesser in 2022 reported through their study, that therapy for metastatic colorectal cancer has significantly improved. Some patients can be cured through a combination of metastasis resection, advanced chemotherapy, and targeted therapy. Personalized treatment based on molecular and clinical factors is crucial for optimal care. Specific subgroups, such as those with dMMR/MSI tumors, HER2 amplification, BRAF V600E mutation, or NTRK fusion, benefit from immunotherapy or targeted therapies. However, most oncogenic drivers in colorectal cancer are currently not druggable, requiring breakthroughs in basic research. Immunotherapy and exploring the immune system in "cold" tumors offer promising avenues for future research [25].

## Conclusion

In conclusion, the use of various genetic testing methods has significantly enhanced the accurate diagnosis of genetic compositions in colon cancer. Studies have demonstrated the effectiveness of DNA sequencing tests in identifying specific genetic mutations in genes such as KRAS, NRAS, and BRAF. PCR tests have proved valuable in detecting specific mutations associated with colon cancer, enabling personalized treatment decisions. FISH tests have shown promise in identifying structural alterations in genes related to colon cancer. These findings highlight the importance of genetic testing in providing precise molecular information for improved diagnosis and tailored treatment approaches in colon cancer. However, it is crucial to consult with healthcare professionals for a comprehensive understanding of the specific tests and their implications in individual cases.

## Acknowledgment

This study has been supported by Global Research, Education and Event Network (GREEN) and International (IAS).

## Conflict of interests

The authors declare that there are no competing interests.

## Reference

[1]. Drake TM, Knight SR, Harrison EM, Søreide K. Global inequities in precision medicine and molecular cancer research. Frontiers in Oncology. 2018;8:346.
[2]. Hoeben A, Joosten EA, van den Beuken-van Everdingen MH. Personalized medicine: Recent progress in cancer therapy. Cancers. 2021;13(2):242.
[3]. Garay JP, Gray JW. Omics and therapy–a basis for precision medicine. Molecular oncology. 2012;6(2):128-39.
[4]. Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of precision medicine. Molecular oncology. 2019;13(3):549-57.
[5]. Ong FS, Das K, Wang J, Vakil H, Kuo JZ, Blackwell WL, Lim SW, Goodarzi MO, Bernstein KE, Rotter JI, Grody WW. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert review of molecular diagnostics. 2012;12(6):593-602.
[6]. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug discovery today. 2015;20(12):1422-8.
[7]. Millner LM, Strotman LN. The future of precision medicine in oncology. Clinics in laboratory medicine. 2016;36(3):557-73.
[8]. Wang Y, Zheng D. The importance of precision medicine in modern molecular oncology. Clinical Genetics. 2021;100(3):248-57.
[9]. Heinemann V, Douillard J, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer–an example of personalised medicine in action. Cancer treatment reviews. 2013;39(6):592-601.
[10]. Molinari C, Marisi G, Passardi A, Matteucci L, De Maio G, Ulivi P. Heterogeneity in colorectal cancer: a challenge for personalized medicine? International journal of molecular sciences. 2018;19(12):3733.
[11]. Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, La Porta ML, Iannaccone A, Micheli F, Santangelo M, Bergantino F, Costantini S, De Luca A. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. Journal of cellular biochemistry. 2013;114(3):514-24.
[12]. Adeniji AA, Dulal S, Martin MG. Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World journal of oncology. 2021;12(2-3):50.
[13]. Morris S. A Decade of Breast Cancer at the Molecular Level: Pioneering Personalized Medicine. 2022.
[14]. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Translational research. 2009;154(6):277-87.
[15]. Sandhu J, Lavingia V, Fakih M. Systemic treatment for metastatic colorectal cancer in the era of precision medicine. Journal of surgical oncology. 2019;119(5):564-82.
[16]. Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert review of gastroenterology & hepatology. 2019;13(10):919-31.
[17]. Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer science. 2018;109(3):513-22.
[18]. Maghvan PV, Jeibouei S, Akbari ME, Niazi V, Karami F, Rezvani A, Ansarinejad N, Abbasinia M, Sarvari G, Zali H, Talaie R. Personalized medicine in colorectal cancer. Gastroenterology and Hepatology From Bed to Bench. 2020;13(Suppl1):S18.
[19]. Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA. Precision medicine in colorectal cancer: the molecular profile alters treatment

strategies. Therapeutic advances in medical oncology. 2015;7(5):252-62.
[20]. Louie BH, Kato S, Kim KH, Lim HJ, Lee S, Okamura R, Fanta PT, Kurzrock R. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Molecular oncology. 2022;16(13):2575-84.
[21]. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertility and sterility. 2018;109(6):952-63.
[22]. Shimada Y, Yagi R, Kameyama H, Nagahashi M, Ichikawa H, Tajima Y, Okamura T, Nakano M, Nakano M, Sato Y, Matsuzawa T, Sakata J, Kobayashi T, Nogami H, Maruyama S, Takii Y, Kawasaki T, Homma KI, Izutsu H, Kodama K, Wakai T. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. Human pathology. 2017;66:1-9.
[23]. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, Bièche I, Rouleau E, Jezdic S, Douillard JY, Reis-Filho JS, Dienstmann R, André F. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2020;31(11):1491-505.
[24]. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA: a cancer journal for clinicians. 2022;72(4):372-401.
[25]. Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology. 2022;14:17588359211072703.